Identification of potential prognostic long non‑coding RNA signatures based on a competing endogenous RNA network in lung adenocarcinoma

Wang,Xiaojuan; Ding,Yawen; Da,Bangming; Fei,Yan; Feng,Gang

doi:10.3892/or.2018.6719

Identification of potential prognostic long non‑coding RNA signatures based on a competing endogenous RNA network in lung adenocarcinoma

Authors:
- Xiaojuan Wang
- Yawen Ding
- Bangming Da
- Yan Fei
- Gang Feng
View Affiliations

Affiliations: Department of Oncology, Wuhan Fourth Hospital (Puai Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, P.R. China
Published online on: September 21, 2018 https://doi.org/10.3892/or.2018.6719
Pages: 3199-3212
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A number of experimental and computational studies have demonstrated the key roles of long non‑coding RNAs (lncRNAs) acting as competing endogenous RNAs (ceRNAs) in the tumorigenesis of lung adenocarcinoma (LUAC). However, there remains a requirement for prognostic candidate biomarkers acting as ceRNAs for the prediction of overall survival in patients with LUAC. The main goal of the present study was to identify novel lncRNAs associated with LUAC overall survival and assess their prognostic values. The study analyzed coding RNA and ncRNA expression profiles of patients with LUAC by retrieving existing RNA‑sequencing datasets from The Cancer Genome Atlas database, and 2,507 differentially expressed mRNAs, 1,633 lncRNAs and 113 miRNAs were screened from patients with LUAC compared with those of adjacent normal samples (P<0.01 and |logFC|>2). Of these LUAC‑specific RNAs, 134 lncRNAs, 21 miRNAs and 34 mRNAs were used to build an lncRNA‑mRNA‑miRNA ceRNA network, among which 8 lncRNAs and 9 mRNAs were associated with overall survival in patients with LUAC by acting as ceRNAs. Next, an lncRNA‑based prognostic signature was constructed by risk scoring approach based on the expression levels of 9 prognosis‑associated lncRNAs using Cox's regression analysis. Moreover, the prognostic capacity of the 9‑lncRNA signature was independent of known clinical prognostic factors. These results provide novel insight into the potential of lncRNA ceRNAs to be candidate biomarkers associated with LUAC overall survival.

View Figures

View References

1	Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, . Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, et al: Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med. 14:822–827. 2008. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Minna JD, Roth JA and Gazdar AF: Focus on lung cancer. Cancer cell. 1:49–52. 2002. View Article : Google Scholar : PubMed/NCBI
4	Sun S, Schiller JH and Gazdar AF: Lung cancer in never smokers-a different disease. Nat Rev Cancer. 7:778–790. 2007. View Article : Google Scholar : PubMed/NCBI
5	Ling H, Fabbri M and Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 12:8472013. View Article : Google Scholar : PubMed/NCBI
6	Mattick JS and Makunin IV: Non-coding RNA. Hum Mol Genet. 15 Suppl 1:R17–R29. 2006. View Article : Google Scholar : PubMed/NCBI
7	Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J and Song E: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 131:1109–1123. 2007. View Article : Google Scholar : PubMed/NCBI
8	Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA and Jacks T: Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA. 105:3903–3908. 2008. View Article : Google Scholar : PubMed/NCBI
9	Faraoni I, Antonetti FR, Cardone J and Bonmassar E: miR-155 gene: A typical multifunctional microRNA. Biochim Biophys Acta. 1792:497–505. 2009. View Article : Google Scholar : PubMed/NCBI
10	Nagano T and Fraser P: No-nonsense functions for long noncoding RNAs. Cell. 145:178–181. 2011. View Article : Google Scholar : PubMed/NCBI
11	Prensner JR and Chinnaiyan AM: The emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407. 2011. View Article : Google Scholar : PubMed/NCBI
12	Weakley SM, Wang H, Yao Q and Chen C: Expression and function of a large non-coding RNA gene XIST in human cancer. World J Surg. 35:1751–1756. 2011. View Article : Google Scholar : PubMed/NCBI
13	Salmena L, Poliseno L, Tay Y, Kats L and Pandolfi PP: A ceRNA hypothesis: The rosetta stone of a hidden RNA language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
14	Wee LM, Flores-Jasso CF, Salomon WE and Zamore PD: Argonaute divides its RNA guide into domains with distinct functions and RNA-binding properties. Cell. 151:1055–1067. 2012. View Article : Google Scholar : PubMed/NCBI
15	Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, Chen N, Sun F and Fan Q: CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 38:5366–5383. 2010. View Article : Google Scholar : PubMed/NCBI
16	Fan M, Li X, Jiang W, Huang Y, Li J and Wang Z: A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of miRNAs in thyroid cancer cells. Exp Ther Med. 5:1143–1146. 2013. View Article : Google Scholar : PubMed/NCBI
17	Sui J, Li YH, Zhang YQ, Li CY, Shen X, Yao WZ, Peng H, Hong WW, Yin LH, Pu YP, et al: Integrated analysis of long non-coding RNAassociated ceRNA network reveals potential lncRNA biomarkers in human lung adenocarcinoma. Int J Oncol. 49:2023–2036. 2016. View Article : Google Scholar : PubMed/NCBI
18	Sui J, Xu SY, Han J, Yang SR, Li CY, Yin LH, Pu YP and Liang GY: Integrated analysis of competing endogenous RNA network revealing lncRNAs as potential prognostic biomarkers in human lung squamous cell carcinoma. Oncotarget. 8:65997–66018. 2017. View Article : Google Scholar : PubMed/NCBI
19	Edge S, Byrd DR, Compton CC, Fritz AG, Greene F and Trotti A: AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. 7th edition. Springer-Verlag; New York, NY: 2010
20	Robinson MD, McCarthy DJ and Smyth GK: edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 26:139–140. 2010. View Article : Google Scholar : PubMed/NCBI
21	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
22	Alizadeh AA, Gentles AJ, Alencar AJ, Liu CL, Kohrt HE, Houot R, Goldstein MJ, Zhao S, Natkunam Y, Advani RH, et al: Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood. 118:1350–1358. 2011. View Article : Google Scholar : PubMed/NCBI
23	Detterbeck FC, Boffa DJ and Tanoue LT: The new lung cancer staging system. Chest. 136:260–271. 2009. View Article : Google Scholar : PubMed/NCBI
24	Suzuki K, Yokose T, Yoshida J, Nishimura M, Takahashi K, Nagai K and Nishiwaki Y: Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Anna Thorac Surg. 69:893–897. 2000. View Article : Google Scholar
25	Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
26	Tay Y, Rinn J and Pandolfi PP: The multilayered complexity of ceRNA crosstalk and competition. Nature. 505:344–352. 2014. View Article : Google Scholar : PubMed/NCBI
27	Amer M, Elhefnawi M, El-Ahwany E, Awad AF, Gawad NA, Zada S and Tawab FM: Hsa-miR-195 targets PCMT1 in hepatocellular carcinoma that increases tumor life span. Tumour Biol. 35:11301–11309. 2014. View Article : Google Scholar : PubMed/NCBI
28	Fu MG, Li S, Yu TT, Qian LJ, Cao RS, Zhu H, Xiao B, Jiao CH, Tang NN, Ma JJ, et al: Differential expression of miR-195 in esophageal squamous cell carcinoma and miR-195 expression inhibits tumor cell proliferation and invasion by targeting of Cdc42. FEBS Lett. 587:3471–3479. 2013. View Article : Google Scholar : PubMed/NCBI
29	Susluer Yilaz S, Avci Biray C, Dodurga Y, Ozlem Dogan Sigva Z, Oktar N and Gunduz C: Downregulation of miR-195 via cyclosporin A in human glioblastoma cells. J BUON. 20:1337–1340. 2015.PubMed/NCBI
30	Chabre O, Libe R, Assie G, Barreau O, Bertherat J, Bertagna X, Feige JJ and Cherradi N: Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocr Relat Cancer. 20:579–594. 2013. View Article : Google Scholar : PubMed/NCBI
31	Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG and Keely PJ: Collagen density promotes mammary tumor initiation and progression. BMC Med. 6:112008. View Article : Google Scholar : PubMed/NCBI
32	Feng Z and Levine AJ: The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol. 20:427–434. 2010. View Article : Google Scholar : PubMed/NCBI